Cardiff Oncology(CRDF) - 2025 Q1 - Quarterly Results

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update SAN DIEGO, May 8, 2025 -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. "Our lead program for onvansertib has remained on track in 2025 with the successful completion of enrollment in our trial in first-line ...